Patents by Inventor Tze Leng Eunice Goh

Tze Leng Eunice Goh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antimicrobial peptides comprising epsilon lysine residues
    Patent number: 11396531
    Abstract: The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2,4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2,4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one a-lysine residue for an ?-lysine residue, and the modified peptides display antimicrobial activity.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: July 26, 2022
    Assignees: Singapore Health Services Pte Ltd, Nanyang Technological University
    Inventors: Lakshminarayanan Rajamani, Venkatesh Mayandi, Tze Leng Eunice Goh, Roger Wilmer Beuerman, Navin Kumar Verma
  • ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES
    Publication number: 20190276505
    Abstract: The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one ?-lysine residue for an ?-lysine residue, and the modified peptides display antimicrobial activity.
    Type: Application
    Filed: October 31, 2017
    Publication date: September 12, 2019
    Inventors: Lakshminarayanan Rajamani, Venkatesh Mayandi, Tze Leng Eunice Goh, Roger Wilmer Beuerman, Navin Kumar Verma